cd25-depleted peripheral blood mononuclear cell
Cell therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2009 (NCT00961376)
Timeline
Indications
Mechanism of action
- leukocytesSupplementation
leukocytes supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cd25/71 allodepleted donor t-cells
- cd25-depleted peripheral blood mononuclear cell
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03912064 | Phase 1 | Apr 26, 2019 | Harvard University |
| NCT01827579 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2014 | Medical Research Council, University of London |
| NCT00961376 | Phase 2 | Jul 1, 2009 | Providence Health & Services |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Medical Research Council | Government | 1 | 0 | 1 | 2014 |
| Providence Health & Services | Academic/Hospital | 1 | 1 | 1 | 2009 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2014 |
4 organizations
Page 1 / 1